A multi-centre, parallel-group, randomised controlled trial to assess the efficacy and safety of eurythmy therapy and tai chi in comparison with standard care in chronically ill elderly patients with increased risk of falling (ENTAiER): a trial protocol

被引:4
|
作者
Kienle, G. S. [1 ,2 ]
Werthmann, P. G. [1 ,2 ]
Grotejohann, B. [3 ]
Kaier, K. [4 ]
Steinbrenner, I. [3 ]
Voigt-Radloff, S. [5 ,6 ]
Huber, R. [1 ]
机构
[1] Univ Freiburg, Ctr Complementary Med, Inst Infect Prevent & Hosp Epidemiol, Med Ctr,Fac Med, Freiburg, Germany
[2] Univ Witten Herdecke, IFAEMM, Freiburg, Germany
[3] Univ Freiburg, Fac Med, Med Ctr, Clin Trials Unit, Freiburg, Germany
[4] Univ Freiburg, Fac Med, Med Ctr, Inst Med Biometry & Stat,Div Methods Clin Epidemi, Freiburg, Germany
[5] Univ Freiburg, Fac Med, Med Ctr, Ctr Geriatr Med & Gerontol Freiburg, Freiburg, Germany
[6] Univ Freiburg, Fac Med, Med Ctr, Inst Evidence Med,Cochrane Germany Fdn, Freiburg, Germany
关键词
Aged; Falls; Prevention; Exercise; Tai chi; Eurythmy therapy; Chronic disease; PHYSICAL-ACTIVITY; OLDER-ADULTS; HIP FRACTURE; HEALTH-CARE; FEAR; INTERVENTIONS; MULTIMORBIDITY; PREVALENCE; PREVENTION; MORTALITY;
D O I
10.1186/s12877-020-1503-6
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background In elderly poeple, multimorbidity and polypharmacy increase while sensory, motor and cognitive functions decrease. Falls occur in 30% of people aged 65 years and older at least once per year, with injuries at 10-20%. Reducing falls and enhancing physical, emotional and cognitive capacities are essential for healthy aging despite chronic disease. Eurythmy therapy (EYT) and Tai Chi train balance, mobility and concentrative and sensory capacities. Methods In eight trial sites (academic or community hospitals), 550 outpatients aged 65 years and older with chronic disease and increased risk of falling (history of imbalance, Berg Balance Scale (BBS) score <= 49) will be randomly assigned (1:1:1) to receive either EYT or Tai Chi (each provided in one-hour group sessions, twice, later once per week plus practice at home, for over 24 weeks) added to standard care or standard care alone. Standard care includes a detailed written recommendation on fall prevention and the visit of a primary care doctor. Seniors living a reclusive life or economically disadvantaged elderly will be particularly addressed. A motivation and communication concept supports the trial participants' compliance with trial procedures and practicing. Public and patient representatives are involved in the planning and conduction of the trial. Falls will be documented daily in a diary by the participants. These falls as well as injuries and complications will be ascertained during monthly phone visits. The falls efficacy scale, BBS, cognition (MoCA), Mood (GDS-15), quality of life (SF12), instrumental activities of daily living (IADL), use of medical and non-medical services (FIMA) and adherence will be assessed at months 3, 6, and 12 and inner correspondence with practices (ICPH) at month 6. The trial is funded by the Federal Ministry of Education and Research (BMBF 01GL1805). Discussion This study will determine whether EYT and Tai Chi reduce falls, injurious falls, fear of falling and healthcare utilisation and improve mobility, cognition, mood, quality of life and functional independence. A reduction of fall risk and fear of falling and an improvement of mobility, autonomy, quality of life, mood, and cognition are highly relevant for older people to cope with aging and diseases and to reduce healthcare costs. Trail registration www.drks.de. DRKS00016609. Registered 30th July 2019.
引用
收藏
页数:12
相关论文
共 46 条
  • [41] Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)]
    Haenggi, Daniel
    Etminan, Nima
    Mayer, Stephan A.
    Aldrich, E. Francois
    Diringer, Michael N.
    Schmutzhard, Erich
    Faleck, Herbert J.
    Ng, David
    Saville, Benjamin R.
    Macdonald, R. Loch
    NEUROCRITICAL CARE, 2019, 30 (01) : 88 - 97
  • [42] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
    Hill, Nathan R.
    Lasserson, Daniel
    Thompson, Ben
    Perera-Salazar, Rafael
    Wolstenholme, Jane
    Bower, Peter
    Blakeman, Thomas
    Fitzmaurice, David
    Little, Paul
    Feder, Gene
    Qureshi, Nadeem
    Taal, Maarten
    Townend, Jonathan
    Ferro, Charles
    McManus, Richard
    Hobbs, F. D. Richard
    TRIALS, 2014, 15 (01)
  • [43] Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
    Nathan R. Hill
    Daniel Lasserson
    Ben Thompson
    Rafael Perera-Salazar
    Jane Wolstenholme
    Peter Bower
    Thomas Blakeman
    David Fitzmaurice
    Paul Little
    Gene Feder
    Nadeem Qureshi
    Maarten Taal
    Jonathan Townend
    Charles Ferro
    Richard McManus
    F. D. Richard Hobbs
    Trials, 23
  • [44] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
    Nathan R Hill
    Daniel Lasserson
    Ben Thompson
    Rafael Perera-Salazar
    Jane Wolstenholme
    Peter Bower
    Thomas Blakeman
    David Fitzmaurice
    Paul Little
    Gene Feder
    Nadeem Qureshi
    Maarten Taal
    Jonathan Townend
    Charles Ferro
    Richard McManus
    FD Richard Hobbs
    Trials, 15 (1)
  • [45] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
    Hill, Nathan R.
    Lasserson, Daniel
    Thompson, Ben
    Perera-Salazar, Rafael
    Wolstenholme, Jane
    Bower, Peter
    Blakeman, Thomas
    Fitzmaurice, David
    Little, Paul
    Feder, Gene
    Qureshi, Nadeem
    Taal, Maarten
    Townend, Jonathan
    Ferro, Charles
    McManus, Richard
    Hobbs, F. D. Richard
    TRIALS, 2014, 15
  • [46] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (vol 15, 160, 2014)
    Hill, Nathan R.
    Lasserson, Daniel
    Thompson, Ben
    Perera-Salazar, Rafael
    Wolstenholme, Jane
    Bower, Peter
    Blakeman, Thomas
    Fitzmaurice, David
    Little, Paul
    Feder, Gene
    Qureshi, Nadeem
    Taal, Maarten
    Townend, Jonathan
    Ferro, Charles
    McManus, Richard
    Hobbs, F. D. Richard
    TRIALS, 2022, 23 (01)